Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Raw Materials (2023 - 2025)

Historic Raw Materials for Catalyst Pharmaceuticals (CPRX) over the last 3 years, with Q3 2025 value amounting to $12.1 million.

  • Catalyst Pharmaceuticals' Raw Materials rose 7471.21% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year increase of 7471.21%. This contributed to the annual value of $6.5 million for FY2024, which is 24125.65% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Raw Materials of $12.1 million as of Q3 2025, which was up 7471.21% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Raw Materials registered a high of $12.1 million during Q3 2025, and its lowest value of $1.9 million during Q4 2023.
  • For the 3-year period, Catalyst Pharmaceuticals' Raw Materials averaged around $6.5 million, with its median value being $6.5 million (2024).
  • In the last 5 years, Catalyst Pharmaceuticals' Raw Materials surged by 24125.65% in 2024 and then crashed by 734.32% in 2025.
  • Quarter analysis of 3 years shows Catalyst Pharmaceuticals' Raw Materials stood at $1.9 million in 2023, then skyrocketed by 241.26% to $6.5 million in 2024, then soared by 86.24% to $12.1 million in 2025.
  • Its Raw Materials was $12.1 million in Q3 2025, compared to $5.2 million in Q2 2025 and $7.4 million in Q1 2025.